These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

5875 related articles for article (PubMed ID: 3457206)

  • 1. Interference with tumor cell-induced degradation of endothelial matrix on the antimetastatic action of nafazatrom.
    Maniglia CA; Loulakis PP; Sartorelli AC
    J Natl Cancer Inst; 1986 Apr; 76(4):739-44. PubMed ID: 3457206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug treatments for metastasis of the Lewis lung carcinoma: lack of correlation between inhibition of lung metastasis and survival.
    Merriman RL; Shackelford KA; Tanzer LR; Campbell JB; Bemis KG; Matsumoto K
    Cancer Res; 1989 Aug; 49(16):4509-16. PubMed ID: 2743339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical study of a new antimetastatic compound, Nafazatrom (Bay g 6575). Effects on platelet consumption and monocyte prostaglandin production in patients with advanced cancer.
    Warrell RP; Bockman RS; Staszewski H; Maiese K
    Cancer; 1986 Apr; 57(8):1455-60. PubMed ID: 2936443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nafazatrom (Bay g-6575), an antithrombotic and antimetastatic agent, inhibits 15-hydroxyprostaglandin dehydrogenase.
    Wong PY; Chao PH; McGiff JC
    J Pharmacol Exp Ther; 1982 Dec; 223(3):757-60. PubMed ID: 6754908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of the stimulation of prostaglandin H synthase and prostacyclin synthase by the antithrombotic and antimetastatic agent, nafazatrom.
    Marnett LJ; Siedlik PH; Ochs RC; Pagels WR; Das M; Honn KV; Warnock RH; Tainer BE; Eling TE
    Mol Pharmacol; 1984 Sep; 26(2):328-35. PubMed ID: 6434940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reaction of the antithrombotic and antimetastatic agent, nafazatrom, with oxidizing radicals.
    Sevilla MD; Neta P; Marnett LJ
    Biochem Biophys Res Commun; 1983 Sep; 115(3):800-6. PubMed ID: 6312995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural requirements for inhibition of melanoma lung colonization by heparanase inhibiting species of heparin.
    Bitan M; Mohsen M; Levi E; Wygoda MR; Miao HQ; Lider O; Svahn CM; Ekre HP; Ishai-Michaeli R; Bar-Shavit R
    Isr J Med Sci; 1995; 31(2-3):106-18. PubMed ID: 7744578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nafazatrom (Bay g 6575) inhibition of tumor cell lipoxygenase activity and cellular proliferation.
    Honn KV; Dunn JR
    FEBS Lett; 1982 Mar; 139(1):65-8. PubMed ID: 6804263
    [No Abstract]   [Full Text] [Related]  

  • 9. Protective actions of nafazatrom in traumatic shock.
    Lefer AM; Messenger M
    Arzneimittelforschung; 1982; 32(9):1089-91. PubMed ID: 6890831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiaggregatory efficacy and its time-course after application of acetylsalicylic acid, prostacyclin and nafazatrom in vivo.
    Herrmann KS
    Arch Int Pharmacodyn Ther; 1984 Nov; 272(1):150-8. PubMed ID: 6393886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigations on the role of arachidonic acid metabolism pathways in the antithrombotic activity of nafazatrom and molsidomine.
    Massad L; Plotkine M; Boulu RG
    Thromb Res; 1988 Jun; 50(5):617-25. PubMed ID: 3137682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mediation of lung metastasis of murine melanomas by a lung-specific endothelial cell adhesion molecule.
    Zhu DZ; Cheng CF; Pauli BU
    Proc Natl Acad Sci U S A; 1991 Nov; 88(21):9568-72. PubMed ID: 1946371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of experimental metastasis and extracellular matrix degradation by butanol extracts from B16-F1 murine melanoma.
    Keren Z; Leland F; Nakajima M; LeGrue SJ
    Cancer Res; 1989 Jan; 49(2):295-300. PubMed ID: 2910449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nafazatrom: in-vitro assessment of radiation and drug activity against animal and human cell lines.
    Haas JS; Haas CD; Kyle GW
    Invest New Drugs; 1984; 2(1):3-6. PubMed ID: 6469496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic cell attachment to and invasion of vascular endothelium and its underlying basal lamina using endothelial cell monolayers.
    Nicolson GL; Irimura T; Nakajima M; Estrada J
    Symp Fundam Cancer Res; 1983; 36():145-67. PubMed ID: 6382504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nafazatrom: clonogenic in-vitro assessment of activity against human malignancies.
    Haas CD; Kyle GW; Crissman JD; Schaldenbrand MF
    Invest New Drugs; 1984; 2(1):7-11. PubMed ID: 6469500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of nafazatrom-induced inhibition of rat uterus contractions in vitro.
    Cantabrana B; Velasco G; Andrès-Trelles F; Hidalgo A
    Arch Int Pharmacodyn Ther; 1989; 301():285-98. PubMed ID: 2560365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nafazatrom (BAY g 6575), a potent stimulator of prostacyclin release from cardiac and renal vessel wall.
    Klitzke AK
    Arch Int Pharmacodyn Ther; 1984 Oct; 271(2):220-8. PubMed ID: 6391401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of myocardial infarction and dysrhythmic activity by nafazatrom in the conscious rat.
    Fiedler VB
    Eur J Pharmacol; 1983 Mar; 88(2-3):263-7. PubMed ID: 6852112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral nafazatrom in man: effect on inhaled antigen challenge.
    Fuller RW; Maltby N; Richmond R; Dollery CT; Taylor GW; Ritter W; Philipp E
    Br J Clin Pharmacol; 1987 Jun; 23(6):677-81. PubMed ID: 3038156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 294.